Singapore Adopts Risk-Based Policy For Devices Under Corrective Action
This article was originally published in PharmAsia News
Executive Summary
Singapore's Health Sciences Authority has adopted a revised policy, effective April 18, under which it will apply a new risk-based approach to decide whether or not to allow medical device companies to continue supplying products affected by a field safety corrective action (FSCA) when the action is still in progress.